Back to top

Myriad Genetics, Inc. (MYGN)

(Delayed Data from NSDQ)

$28.41 USD


-0.17 (-0.60%)

Updated Apr 25, 2018 04:00 PM ET

Add to portfolio

2-Buy   2      

B Value | D Growth | D Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.71%
2 Buy 18.12%
3 Hold 9.91%
4 Sell 5.49%
5 Strong Sell 2.29%
S&P 500 9.79%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Company Summary

Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering innovative products that transform patients' lives. These products include leading molecular diagnostic tests for hereditary cancer, urological cancer, lung cancer, autoimmune disorders and other diseases. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Myriad's hereditary cancer genetic testing, which helps healthcare professionals better manage and tailor medical care. Myriad is expanding their reach and increasing their impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.

General Information

Myriad Genetics, Inc.



Phone: 801-584-3600

Fax: 801-584-3640



Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End June
Last Reported Quarter 3/31/2018
Next EPS Date 5/1/2018

EPS Information

Current Quarter EPS Consensus Estimate 0.27
Current Year EPS Consensus Estimate 1.15
Estimated Long-Term EPS Growth Rate 10.00
Next EPS Report Date 5/1/2018

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 28.58
52 Week High 41.57
52 Week Low 18.04
Beta 0.52
20 Day Moving Average 610,555.88
Target Price Consensus 33.36


% Price Change
4 Week -2.76
12 Week -26.53
YTD -16.79
% Price Change Relative to S&P 500
4 Week -3.57
12 Week -21.29
YTD -15.08
Share Information
Shares Outstanding (millions) 69.85
Market Capitalization (millions) 1,996.32
Short Ratio NA
Last Split Date 3/26/2009
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E (F1) 24.75
Trailing 12 Months 25.07
PEG Ratio 2.48
EPS Growth
vs. Previous Year 19.23%
vs. Previous Quarter 19.23%
Sales Growth
vs. Previous Year -1.27%
vs. Previous Quarter 2.00%
Price Ratios
Price/Book 2.16
Price/Cash Flow 16.13
Price / Sales 2.55
3/31/18 NA
12/31/17 9.59
9/30/17 9.54
3/31/18 NA
12/31/17 6.42
9/30/17 5.97
Current Ratio
3/31/18 NA
12/31/17 2.05
9/30/17 2.34
Quick Ratio
3/31/18 NA
12/31/17 1.81
9/30/17 2.06
Operating Margin
3/31/18 NA
12/31/17 10.16
9/30/17 9.51
Net Margin
3/31/18 NA
12/31/17 16.67
9/30/17 13.28
Pre-Tax Margin
3/31/18 NA
12/31/17 14.98
9/30/17 16.01
Book Value
3/31/18 NA
12/31/17 13.20
9/30/17 12.58
Inventory Turnover
3/31/18 NA
12/31/17 4.18
9/30/17 3.88
3/31/18 NA
12/31/17 0.05
9/30/17 0.09
Debt to Capital
3/31/18 NA
12/31/17 4.51
9/30/17 7.85